Subscribe

Snapshot

DOI:

Continue learning with EuroIntervention!

With the excitement of EuroPCR now in the past – and it was a wonderful moment to reconnect with colleagues and learn together – we move forward with thoughtful, original research on topics encompassing devices, techniques and, of course, the well- being of our patients.

Short DAPT after NSTE-ACS in HBR patients

Davide Cao, Roxana Mehran and colleagues compare the impact of 1 versus 3 months of dual antiplatelet therapy on the clinical outcomes of high bleeding risk patients undergoing percutaneous coronary intervention (PCI) due to non-ST-segment elevation acute coronary syndrome or chronic coronary syndrome. In their findings, a very short duration of dual antiplatelet therapy appears to be a valid bleeding avoidance strategy for these patients.

Early discharge after large-bore CTO PCI

Same-day discharge can augment patient comfort and decrease economic costs, but is this a feasible and safe practice for patients undergoing large-bore chronic total occlusion PCI? Yvemarie B.O. Somsen, Paul Knaapen and colleagues examine a CTO PCI registry and find that same-day discharge was achieved successfully in over 60% of patients, with low rates of overall vascular access complications.

Impact of calcium morphologies on IVL efficacy

Although calcium modification is recommended before stenting, do different calcium morphologies impact the efficacy of intravascular lithotripsy? Angela McInerney, Nieves Gonzalo and colleagues use optical coherence tomography to assess final stent parameters in patients undergoing intravascular lithotripsy for the treatment of calcified coronary artery disease.

Ultrathin-strut versus thin-strut BP-SES: healing and outcomes

Ryutaro Ikegami, Farouc A. Jaffer and colleagues study how the strut thickness of ultrathin-strut versus thin-strut biodegradable-polymer sirolimus-eluting stents impacts vessel healing and clinical outcomes at 30 days and 1 year. Given that the clinical outcomes were similar, they postulate that the benefits of biodegradable-polymer sirolimus-eluting stents may be independent of the strut thickness.

Volume 20 Number 10
May 20, 2024
Volume 20 Number 10
View full issue

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00022 Sep 15, 2025
An ongoing quest to discern the optimal antithrombotic therapy after TAVI
Hayashida K and Iwata J
free

Translational research

10.4244/EIJ-D-24-01000 Sep 15, 2025
DurAVR – a novel biomimetic balloon-expandable transcatheter valve for TAVI, valve-in-valve TAVI and redo-TAVI
Meier D et al
open access

Research Correspondence

10.4244/EIJ-D-25-00255 Sep 15, 2025
Redo-TAVI with the ACURATE platform for failure of short-frame transcatheter heart valves
Tarantini G et al

Original Research

10.4244/EIJ-D-24-01066 Sep 15, 2025
VARC-HBR criteria validation in TAVI patients on oral anticoagulation
Overduin D et al

Editorial

10.4244/EIJ-E-25-00038 Sep 15, 2025
Evolving cutoff values for optimising left main stenting with intravascular imaging
de la Torre Hernandez J
free

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free

Flashlight

10.4244/EIJ-D-25-00121 Sep 15, 2025
Calcium mapping by 3DStent technology
Amabile N and Benamer H
Trending articles
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
48.8

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
28.25

Clinical research

10.4244/EIJ-D-19-01006 Aug 7, 2020
Coronary collaterals and myocardial viability in patients with chronic total occlusions
Schumacher S et al
free
Chat with Cory
Hello , I'm Cory and I will do my best to answer your questions about this article. Please remember that this is an experimental feature, and that I'm still learning.
Can you provide a summary of the key findings in this article?
Can you extract and explain the primary hypothesis or research question addressed in this article?
What are the potential clinical applications or implications of the results presented in this paper?
How does this research contribute to our current understanding of cardiovascular disease management?
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved